key: cord-0713898-xqls2x2d
authors: Liu, Renqiang; Wen, Zhiyuan; Wang, Jinling; Ge, Jinying; Chen, Hualan; Bu, Zhigao
title: Absence of Middle East respiratory syndrome coronavirus in Bactrian camels in the West Inner Mongolia Autonomous Region of China: surveillance study results from July 2015
date: 2015-12-02
journal: Emerg Microbes Infect
DOI: 10.1038/emi.2015.73
sha: 8dd14ffdb898c891d284cff71623b3e43ec0b0fe
doc_id: 713898
cord_uid: xqls2x2d

nan

(50 camels sampled) in Ordos (Table 1) . Serum and nasal swab samples were collected from each camel.

The presence or absence of MERS-CoV neutralizing antibodies in the serum samples was determined by using a recombinant chimeric vesicular stomatitis virus (VSV), rVSVDG/S-eGFP. This virus was generated by using reverse genetics and was based on rVSV-eGFP, a recombinant VSV expressing enhanced green fluorescence protein (eGFP). 8 In the genome of rVSV-eGFP, the ORF of VSV G was replaced with that of MERS-CoV spike protein (S). rVSVDG/S-eGFP can infect host cells by utilizing MERS-CoV S to mediate viral attachment and entry; expression of eGFP is an indicator of the infection. Serum from a recombinant Newcastle disease virus expressing MERS-CoV S (rNDV-MERS-CoV-S)-immunized camel served as a control. The method for generating rNDV-MERS-CoV-S was described previously. 9 Neutralization titers were expressed as the reciprocal of the highest dilution of serum that showed at least 50% inhibition of infection with rVSVDG/S-eGFP. All serum samples and the control serum from pre-immunized camels had neutralization antibody titers against rVSVDG/S-eGFP of less than 1:2. In contrast, the control serum from the rNDV-MERS-CoV-S immunized camel yielded neutralization antibody titer of 1:512. An enzyme-linked immunosorbent assay was also carried out to test for MERS-CoVspecific antibodies in serum samples. Vero E6 cells were infected with rVSVDG/S-eGFP, and the lysate of infected Vero E6 cells was used as the coating antigen for the ELISA. Specific antibody binding to MERS-CoV S was detected with HRP-conjugated Protein A and visualized by adding 3,39,5,59-tetramethylbenzidine substrate. All serum samples and control sera from pre-immunized camels yielded OD 450 values of between 0.17 and 0.29; however, the control serum from the postimmunized camel yielded OD 450 value of 0.51. The swab samples were tested by using real-time polymerase chain reaction (RT-PCR) targeted to ORF1a of the MERS-CoV genome in accordance with the World Health Organisation protocol. 10 The results showed that all of the samples were negative for MERS-CoV ORF1a RNA.

In the present study, a total of 190 Bactrian camels from 10 herds were sampled in three areas of the West IMAR of China, where over 40% of the Bactrian camels in China are raised. All 190 serum and swab samples were negative for MERS CoV S-specific neutralizing antibody, ELISA antibody, and MERS-CoV RNA. Our results indicate that there is no MERS-CoV circulating among Bactrian camels in the West IMAR. The absence of MERS-CoV infection in Bactrian camels in other areas of China should be confirmed through further surveillance studies.

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

European Centre for Disease Prevention and Control. Epidemiological update: Middle East respiratory syndrome coronavirus (MERS-CoV)

Sejong: Korea Ministry of Health and Welfare

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study

A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus

Evidence for camel-to-human transmission of MERS coronavirus

Absence of MERS-Coronavirus in Bactrian Camels

The NS1 gene contributes to the virulence of H5N1 avian influenza viruses

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses

Laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV). Geneva: WHO

We thank Michael Whitt (University of Tennessee Health Science Center, Memphis, USA) for providing the reverse genetics system for generating the recombinant rVSVDG/S-eGFP. This study was supported by the National Key Technology R&D Program (2013BAD12B05).

This work is licensed under a Creative Commons Attribution 4.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/